CURCUMIN-CWS (60 Day Supply)
Curcumin is generally known as a remedy for a wide range of disorders and diseases*. But it shows very poor uptake efficiency, hence little amounts of the taken curcumin reach targets distant from the gut.
HIGHLY BIOAVAILABLE CURCUMIN (HBA)
Curcumin and its derivatives, commonly known as curcuminoids, are biologically active constituents of the herb curcuma longa or turmeric. Curcumin is a powerful antioxidant: it has been shown to exhibit remarkable joint function anti-inflammatory effects.
The bioavailability of diet-derived polyphenols varies greatly and curcumin is known not to be readily absorbed by the body. Scientists developed a solution for increasing the bioavailability of functional ingredients and offers one of the highest bioavailable curcumin formulations
Human Bioavailability in a Clinical Study
Eur J Nutr. 2018; 57(3): 929–938.
The relative absorption of Curcumin CWS was compared to standard 95% curcumin extract and two leading commercial products claiming to have enhanced bioavailability in a clinical setting.
12 individuals (fasted overnight) were given three different bioavailable curcumin preparations and standard curcumin orally – with a one-week washout period in between the four formulations. After product intake, blood was drawn hourly for 12 hours and analyzed (spiked plasma samples). Blood concentration and the relative absorption of curcumin and its derivatives were determined.
CWS was around 40 times more efficiently absorbed compared to pure curcumin powder and some leading commercial curcumin supplement products. The highly superior performance of CWS was demonstrated by the fact that the curcumin uptake was at least 4.6 times higher than the next-best commercial curcumin formulation in this clinical study.
These results clearly underline the significant increase in bioavailability of curcumin in a cyclodextrin-based formulation. Furthermore, these data suggest that CURCUMIN– CWS can provide the benefits of the powerful antioxidant curcumin to a much greater extent than existing commercial products.
In Vivo Bioavailability in a Rodent Model (2009)
Total concentrations of curcuminoids in the blood plasma (0-4 hours) of Sprague Dawley rats were recorded after one oral gavage (500 mg/kg body weight) of three curcumin preparations: standard curcumin extract, brand name curcumin (= CP) and CURCUMIN-CWS. Plasma was analyzed for free curcumin and curcumin metabolites (curcumin sulfates and curcumin glucuronides) by HPLC (0-4 hours).
Animals that received CURCUMIN-CWS showed a 10 to 20 times higher amount of total curcuminoids in their blood plasma, expressed as the sum of free curcumin and its metabolites, than animals that received a commercial product or pure curcumin powder.
This huge difference in HPLC-measured curcumin metabolites indicates that a maximum amount of curcumin was delivered into the blood stream of the rats, which can only be explained by the very highly CURCUMIN-CWS.
In Vitro Bioavailability in a Human Caco-2 Model (2011))
The dissolution profile of five curcumin preparations (standard curcumin extract, three leading brand name curcumin products = “CP” and CURCUMIN-CWS in simulated intestinal fluid (SIF, 0.5% SDS) followed by the uptake of Caco-2 cells (human gut cell model) was investigated.
CURCUMIN-CWS was up to five times more efficiently dissolved compared to leading commercial curcumin supplement products or curcumin powder itself.
The following uptake study with human Caco-2 cells also demonstrates a superior performance by CURCUMIN-CWS. The uptake was up to 10 times higher than for other leading commercial curcumin formulations or curcumin powder itself.
Curcumin has been widely used for centuries and is a well-known substance used in the traditional Ayurvedic approach to nutrition. Modern science has provided a solid basis for such uses and current clinical trials make curcumin one of the best investigated natural compounds to date.
The most recent human clinical studies are summarized below:
- Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study ( Kuptniratsaikul u. a., 2014)
- Ability of curcuminoid compared to diclofenac sodium in reducing the secretion of cycloxygenase-2 enzyme by synovial fluid’s monocytes of patients with osteoarthritis ( Kertia u. a., 2012)
- The efficacy of Curcuma Longa L. extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial ( Pinsornsak und Niempoog, 2012)
- Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis ( Kuptniratsaikul u. a., 2009)
- Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study ( Suskind et al., 2013)
- Effects of various food ingredients on gall bladder emptying ( Marciani et al., 2013)
- Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial ( Hanai et al., 2006)
- Curcumin therapy in inflammatory bowel disease: a pilot study ( Holt et al., 2005)
- MGAT3 mRNA: a biomarker for prognosis and therapy of Alzheimer’s disease by vitamin D and curcuminoids ( Fiala et al., 2011)
- 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients ( Masoumi et al., 2009)
Blood Lipid Levels*
- Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. ( Yang et al., 2014)
- Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial ( Na et al., 2013)
- Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects ( Pungcharoenkul and Thongnopnua, 2011)
- Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients ( Ryan et al., 2013)
- Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study ( Golombick et al., 2012)
- Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia ( Carroll et al., 2011)
- Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin ( He et al., 2011)
- Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer ( Bayet-Robert et al., 2010)
- Curcumin and gemcitabine in patients with advanced pancreatic cancer ( Epelbaum et al., 2010)
- What is the difference between turmeric, curcuma longa and curcumin?
Curcumin is the principal curcuminoid found in turmeric. Turmeric is a rhizome with the botanical name “curcuma longa.” The curcuminoid curcumin is considered its most active component. Other curcuminoids present in turmeric rhizomes are demethoxycurcumin and bis-demethoxycurcumin.
- What is the difference between curcuma longa (curcumin) extract and CURCUMIN-CWS?
Curcuma longa or turmeric extract is usually standardized to 95% curcuminoids consisting of about 65-80% curcumin,15-20% demethoxycurcumin and 2-5% bis-demethoxycurcumin.
CURCUMIN-CWS is a physical mixture of gamma-cyclodextrin and a 95% turmeric (curcuma longa) extract (not just curcumin). Gamma-cyclodextrin is a non-allergenic, vegetarian oligosaccharide used as hydrophilic carrier to improve the bioavailability of the water-insoluble curcuminoids, especially curcumin, by a factor greater than 40.
- How is CURCUMIN-CWS different from other bioavailable curcumin products?
CURCUMIN-CWS consists only of curcuminoids and a safe hydrophilic carrier gamma-cyclodextrin. Gamma-cyclodextrin is a non-allergenic, vegetarian oligosaccharide.
CURCUMIN-CWS clinically demonstrated a bioavailability that was more than 40 times better than standard 95% turmeric (curcuma longa) extract and exhibited significantly higher relative absorption when compared to other leading bioavailable commercial curcumin products. The bioavailability of CURCUMIN-CWS was assessed in a double-blind, cross-over human study comparing our product not only with a standard but also with the two leading competitor formulations. The study was conducted with a verifiable low-fat diet to exclude the effect of fat/oil on the absorption of curcumin.
- What pre-clinical and clinical studies have been done?
An in vivo bioavailability study in a rodent model (conducted in Canada, 2009):
Plasma curcumin concentrations (0-4 hours) of rats were recorded after oral gavage of one dose of CURCUMIN-CWS . Animals that received CURCUMIN-CWS showed a 10 to 20 times higher amount of total curcuminoids in their blood plasma, expressed as the sum of free curcumin and its metabolites, than animals that received a commercial supplement product or pure 95% turmeric (curcuma longa) extract powder
An in vitro bioavailability in a (human) Caco-2 model (conducted in Germany, 2011):
The dissolution profile in simulated intestinal fluid (SIF, 0.5% SDS) followed by the uptake of Caco-2 cells (human gut cell model) was investigated. CURCUMIN- CWS® was up to five times more efficiently dissolved compared to three leading commercial curcumin supplement products or 95% turmeric (curcuma longa) extract powder itself. The uptake of Caco-2 cells was up to 10 times higher than for other leading commercial curcumin formulations or 95% turmeric (curcuma longa) extract powder itself. These results clearly underline the significant increase in bioavailability of curcumin in a gamma-cyclodextrin-based formulation.
Human bioavailability in a clinical study (conducted in the US, 2013):
In a clinical setting, the relative absorption of CURCUMIN- CWS® was compared to standard 95% turmeric (curcuma longa) extract and two leading commercial products claiming to have enhanced bioavailability. The results showed that CURCUMIN- CWS was around 40 times more efficiently absorbed compared to curcumin extract powder itself and at least 4.4 times better than the next-best commercial curcumin formulation in this clinical study.
- Is CURCUMIN-CWS tested for heavy metals?
Every batch of CURCUMIN-CWS produced is tested at an external lab for heavy metals including lead, arsenic, cadmium and mercury.
- Is CURCUMIN-CWS allergen-free?
Yes, CURCUMIN-CWS is free of allergens.1
- What is the recommend dosage for CURCUMIN-CWS?
The recommended daily dosage for CURCUMIN-CWS is 1-2 g/day. Please consult your physician or healthcare professional before consuming any supplements including CURCUMIN-CWS.
- Is CURCUMIN-CWSsafe?
Curcumin has been widely used for centuries and is a well-known substance used in the traditional Ayurvedic approach to nutrition. Modern science has provided a solid basis for such uses and current clinical trials make curcumin one of the best investigated natural compounds to date. A positive safety profile at doses of 8-10 grams has been published in several clinical studies. CURCUMIN-CWS has been investigated in a human bioavailability study (15 individuals) with a dosage of 2 grams per day showing no adverse effects. The curcumin blood plasma levels achieved in the study are comparable to blood plasma levels reported in scientific literature as being safe.
*These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.